MedTrace Logo

Nicotinamide Supplementation in Glaucoma

NCT06731582 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2024-12-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if nicotinamide (NAM, vitamin B3) supplementation can delay glaucoma progression 30% above that achieved with conventional glaucoma treatment using topical medication. The main questions it aims to answer are:

Can NAM supplementation improve the visual function of patients with glaucoma measured by visual field perimetry?

Researchers will compare NAM to a placebo (a look-alike substance that contains no drug) to see if NAM works as an adjuvant in glaucoma treatment.

Participants will:

* Take NAM or a placebo every day for 2 years
* Visit the clinic once every 3-4 months for checkups and tests

Conditions

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Tablet

1.5 grams/day

DIETARY_SUPPLEMENT

Nicotinamide Placebo

2 tablets

Sponsors & Collaborators

  • National University Hospital, Singapore

    collaborator OTHER

  • Singapore National Eye Centre

    collaborator OTHER_GOV

  • Singapore Eye Research Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-12
Primary Completion
2027-07-31
Completion
2028-07-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06731582 on ClinicalTrials.gov